Case Report - (2019) Volume 10, Issue 2

Potential of Germline CDKN2A I49T as a Targetable Driver Mutation: Prolonged Control of Refractory Osteosarcoma with CDK4/6 Inhibitor in a Familial Cancer

Omid S Tehrani1*, Haifaa Abdulhaq2 and Celia D Delozier2
1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
2Division of Oncology, Department of Medicine, UCSF Fresno, CA, USA
*Corresponding Author: